Business Context and Reporting Period
This Form 8-K Current Report, dated June 13, 2025, covers corporate governance changes for Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation). The filing reports a legal name change effective June 13, 2025, and an upcoming ticker symbol change on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes and does not contain financial performance data.
Material Changes
- Corporate Name: Changed from "Oncocyte Corporation" to "Insight Molecular Diagnostics Inc." effective June 13, 2025.
- Trading Symbol: The ticker symbol will change from "OCX" to "IMDX" effective before market open on June 18, 2025.
- Legal Mechanism: The name change was executed via a merger of a wholly-owned subsidiary into the parent company under Section 1110(d) of the California Corporations Code.
- Shareholder Rights: The change does not affect security holder rights, did not require shareholder approval, and the CUSIP number remains unchanged.
Guidance, Outlook, and Risks
The filing includes a press release and a letter from CEO Joshua Riggs dated June 17, 2025, regarding the rebranding. The document explicitly states that the information furnished under Item 7.01 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act. No specific financial guidance, operational outlook, or new risk factors are disclosed in this text.
Investor Verification Checklist
- Verify the new ticker symbol "IMDX" begins trading on June 18, 2025.
- Confirm that existing holdings under "OCX" automatically convert to "IMDX" without action required by the investor.
- Review the attached Certificate of Ownership (Exhibit 3.1) and Third Amended and Restated Bylaws (Exhibit 3.2) for full legal details.
- Check subsequent filings for any strategic rationale or financial impact associated with the rebranding.